Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
Last updated: 2025-12-10 09:30:37 ET
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
Megaprojects are boosting the building pipeline as overall momentum dips for a second consecutive month, according to Dodge Construction Network.
Nonresidential Planning Pipeline Continues to Settle BOSTON, MA – December 5, 2025 — The Dodge Momentum Index (DMI), issued by Dodge Construc...
Arkansas county jail becomes major ICE hub with 450 arrests in 10 months - averaging 1.5 detentions daily in Benton County's immigration crackdow...
Boston, Dec. 04, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, "Global Market for Hydrogen Pipeline" is projected to re...
Salesforce said its earnings reflect AI momentum. Will the results be enough to flip bearish sentiment for an extended stretch?